Conditions: HIV Infection
Keywords: treatment experienced
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 355
Healthy volunteers: no

Brief summary:
The purpose of this study is to investigate the efficacy, safety, and tolerability of an investigational treatment for patients with Human Immunodeficiency Virus (HIV).

Detailed description:

Arms:
arm 1: Raltegravir \& Placebo arm 2: Lopinavir (+) Ritonavir \& Placebo

Interventions: intervention 1: Comparator: raltegravir intervention 2: Comparator: placebo intervention 3: Comparator: lopinavir (+) ritonavir intervention 4: Comparator: placebo
Intervention descriptions: intervention 1: raltegravir 400 milligram (mg) by mouth (PO) twice daily (b.i.d) for up to 48 weeks of treatment intervention 2: lopinavir (+) ritonavir 400/100 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment intervention 3: lopinavir (+) ritonavir 400/100 mg by mouth (PO) twice daily (b.i.d.) for up to 48 weeks of treatment intervention 4: raltegravir 400 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment

Protocol document: